Compound useful as reversible inhibitors of cysteine proteases

US6420364B1 · kind B1 · utility

Assignee

• Boehringer Ingelheim Pharmaceuticals, Inc. · US

Inventors

• Michel Jose Emmanuel · New Fairfield, US
• Leah L. Frye · Patterson, US
• Eugene Richard Hickey · Danbury, US
• Weimin Liu · Sandy Hook, US
• Tina Morwick · New Milford, US
• Denice Spero · West Redding, US
• Sanxing Sun · Danbury, US
• David Thomson · Ridgefield, US
• Yancey David Ward · Sandy Hook, US
• Erick Richard Roush Young · Danbury, US

Key dates

• Filing date: Sep 8, 2000
• Grant date: Jul 16, 2002
• Expiry date: Sep 8, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.